Semi-Annual Report — FY2026 H1
What Medrx Co.,Ltd. reported for the period from 2026-01-01 to 2026-12-31. Filed by 株式会社メドレックス
Filed 2026-08-07View the original on EDINET
How much it says
49Typical
What moved here
18named for the first time
Its own wording
36terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, development of the major pipeline products continued. The filing describes execution of the basic terms for Bondlido’s sales partnership and clinical progress for MRX-4TZT and Alto-101, including preliminary POC results for Alto-101. Meanwhile, financial performance deteriorated, with lower revenue and operating and interim net losses recorded, and the effective date of the reduction in capital and capital reserves, 2 May 2026, was specified.
Komori's summary of this document, not the document's own words.49Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
38
Thin
49
Typical
38
Thin
75
Very detailed
15
Almost nothing
53
Typical
55
Typical
7
Almost nothing
79
Very detailed
50
Typical
R&D spend4億円Money spent making new things.
Cash left over-7億円Cash from the business, less what went into equipment.
Spent on equipment3百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.